NCT03992417

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

A Prospective Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 955 (actual)
• Sponsor: Sanofi · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD Secondary Objectives: * To characterize real-world use patterns of Dupixent® for AD (eg, used regimens, reason for initiation of new treatments, concomitant therapies, treatment durations and reasons for discontinuation and/or switching) * To assess the long-term effectiveness of Dupixent® in AD patients in a real-world setting * To assess comorbid atopic conditions and effects of treatment in comorbid atopic conditions in patients who receive Dupixent® for AD * To collect safety data on study participants

Detailed description

Participants enrolled in the study will be followed for 5 years.

Conditions

• Dermatitis Atopic

Interventions

Type	Name	Description
DRUG	Dupilumab SAR231893 (REGN668)	Pharmaceutical form: solution for injection Route of administration: subcutaneous injection

Timeline

• Start date: 2019-06-11
• Primary completion: 2027-03-31
• Completion: 2027-03-31
• First posted: 2019-06-20
• Last updated: 2025-07-11

Locations

114 sites across 22 countries: Argentina, Australia, Austria, Belgium, Colombia, Czechia, Finland, France, Greece, Israel, Italy, Japan, Kuwait, Mexico, Netherlands, Norway, Portugal, Russia, Saudi Arabia, Spain, Taiwan, United Arab Emirates